An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive survival outcomes in patients with resected pancreatic and colorectal cancers, according to final results from the phase I AMPLIFY-201 trial.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small UCLA clinical trial suggests.